Aileron Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own9.02% Shs Outstand90.67M Perf Week-38.70%
Market Cap23.29M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float82.63M Perf Month-43.42%
Income-27.60M PEG- EPS next Q-0.09 Inst Own35.60% Short Float0.24% Perf Quarter-52.52%
Sales- P/S- EPS this Y51.40% Inst Trans-3.73% Short Ratio0.57 Perf Half Y-54.57%
Book/sh0.40 P/B0.61 EPS next Y5.30% ROA-54.10% Target Price3.00 Perf Year-81.43%
Cash/sh0.40 P/C0.61 EPS next 5Y2.10% ROE-59.30% 52W Range0.25 - 1.31 Perf YTD-56.78%
Dividend- P/FCF- EPS past 5Y24.90% ROI- 52W High-81.43% Beta2.34
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low-3.64% ATR0.05
Employees9 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)25.95 Volatility20.68% 13.09%
OptionableNo Debt/Eq0.00 EPS Q/Q-11.00% Profit Margin- Rel Volume3.31 Prev Close0.26
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume345.74K Price0.24
Recom1.70 SMA20-39.40% SMA50-42.59% SMA200-59.10% Volume1,143,925 Change-6.42%
Jul-24-17Initiated William Blair Outperform
Jul-24-17Initiated Jefferies Buy $20
Jul-24-17Initiated BofA/Merrill Buy $19
Jun-29-22 09:46AM  
May-19-22 07:00AM  
May-17-22 07:00AM  
May-13-22 07:00AM  
May-11-22 07:57AM  
May-10-22 12:43PM  
May-05-22 04:15PM  
Apr-21-22 09:40AM  
Apr-05-22 09:40AM  
Mar-28-22 04:20PM  
Mar-22-22 08:04AM  
Jan-27-22 01:38PM  
Jan-05-22 08:04AM  
Jan-04-22 08:45AM  
Dec-30-21 04:32AM  
Dec-20-21 10:56AM  
Nov-12-21 07:50AM  
Oct-07-21 09:22AM  
Sep-30-21 04:30PM  
Sep-16-21 02:33PM  
Sep-10-21 08:30AM  
Sep-07-21 04:05PM  
Aug-27-21 09:48AM  
Aug-11-21 04:20PM  
Jul-08-21 08:15AM  
Jul-01-21 01:39PM  
Jun-30-21 09:33AM  
Jun-24-21 07:00AM  
May-19-21 07:00AM  
May-11-21 04:18PM  
Mar-24-21 04:36PM  
Mar-04-21 08:30AM  
Mar-02-21 07:00AM  
Jan-11-21 06:30AM  
Jan-06-21 09:30AM  
Dec-23-20 03:41AM  
Dec-21-20 08:00AM  
Dec-14-20 08:32AM  
Dec-01-20 10:12AM  
Nov-29-20 08:33PM  
Nov-24-20 08:28AM  
Nov-19-20 10:02AM  
Nov-12-20 07:03PM  
Oct-24-20 04:35AM  
Oct-20-20 09:24AM  
Oct-13-20 08:30AM  
Oct-12-20 07:00AM  
Sep-21-20 06:07PM  
Sep-10-20 08:45AM  
Aug-25-20 01:25PM  
Aug-05-20 04:10PM  
Aug-04-20 03:31PM  
Aug-03-20 08:10AM  
Jun-29-20 08:30AM  
Jun-12-20 11:42AM  
Jun-10-20 09:54AM  
Jun-04-20 09:15AM  
Jun-03-20 04:01PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-27-20 08:30AM  
May-11-20 08:30AM  
Apr-22-20 08:30AM  
Mar-30-20 04:16PM  
Dec-20-19 05:45PM  
Dec-19-19 06:07AM  
Dec-18-19 08:30AM  
Nov-07-19 07:30AM  
Oct-31-19 08:30AM  
Oct-29-19 08:00AM  
Oct-21-19 08:00AM  
Oct-16-19 08:30AM  
Sep-28-19 07:30AM  
Sep-24-19 05:00PM  
Sep-19-19 07:24AM  
Sep-09-19 08:00AM  
Sep-03-19 05:10PM  
Aug-06-19 04:10PM  
Jul-30-19 07:03PM  
Jul-17-19 02:38PM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
May-30-19 08:00AM  
May-08-19 04:57PM  
May-01-19 06:31PM  
Apr-03-19 12:15PM  
Mar-29-19 09:00AM  
Mar-04-19 09:00AM  
Feb-01-19 02:31PM  
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.